Evidence map›Paper›PMID 41165877›Full record

ArticleWorld journal of urology2025

Exploration of a novel quantitative model based on PRIMARY score in the diagnosis of clinically significant prostate cancer using [18F]PSMA PET/CT.

Haiyan Gao, Bo Chen, Zhichuan Yang, Juan Su, Yujue Li, Nan Liu, Yunfei Xie, Zhaohui Liu, Wei Xiong, Ziyang Zhu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Prospective evaluation of the PRIMARY score using [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Haiyan Gao *Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Bo Chen *Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Zhichuan Yang *Department of Emergency Surgery, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, 610041, China.
Juan SuDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Yujue LiDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Nan LiuDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Yunfei XieDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Zhaohui LiuDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China.
Wei XiongDepartment of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China. xiongweimd@gmail.com.
Ziyang ZhuDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China. zhuziyang@med.uestc.edu.cn.
Wei ZhangDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan Province, China. zhangwscd@uestc.edu.cn.

Funding

Sichuan Science and Technology Program 2024NSFSC0667
6 · The paper itself

Abstract

objectiveTo evaluate the feasibility and efficacy of the Quantitative-PRIMARY (Q-PRIMARY) model based on the PRIMARY score for diagnosing clinically significant prostate cancer (csPCa) using [18F]PSMA-1007 PET/CT.

methodsA total of 324 consecutive patients were prospectively enrolled and retrospectively analyzed. Cohort assignment was based on the availability of in-house multiparametric MRI: a training cohort (n = 222, no in-house MRI) and an internal validation cohort (n = 102, with in-house MRI). Histopathology from systematic 12-core biopsy or radical-prostatectomy specimens served as the reference standard. We developed the Q-PRIMARY model by integrating visual PRIMARY scores with quantitative SUV-based thresholds (ΔSUVpeak, SUVmax, SUVR) for each PRIMARY category (scores 2-4).

resultsThere were 27, 41, 33, and 46 patients in the four groups, with positive lesions found in 62%, 62%, 53.53%, and 65.08%, respectively. Optimal diagnostic parameters for csPCa included ΔSUVpeak, SUVmax, SUVratio (SUVR), and SUVmax. The areas under the curve (AUC) ranged from 0.888 to 0.944, with high sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The Q-PRIMARY demonstrates superior diagnostic accuracy and clinical benefits compared to MRI PI-RADS, with more stable performance in AUC (0.978 vs. 0.768), sensitivity (97.18% vs. 92.96%), specificity (96.77% vs. 54.84%), PPV (98.60% vs. 82.50%), NPV (93.70% vs. 77.30%), and clinical decision curve analysis (DCA).

conclusionIn this selected high-risk cohort, the [18F]PSMA-1007 PET/CT Q-PRIMARY framework delivered high diagnostic performance and complemented multiparametric MRI. External prospective validation is warranted before clinical adoption.

Indexed as

NiacinamidePositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedFeasibility StudiesFluorine RadioisotopesHumansMaleMiddle AgedMultiparametric Magnetic Resonance ImagingOligopeptidesProspective StudiesRadiopharmaceuticalsRetrospective StudiesFluorine RadioisotopesNiacinamideOligopeptidesPSMA-1007RadiopharmaceuticalsMRIPET/CTPRIMARY scoreProstate cancerProstate-specific membrane antigen

Identifiers

PMID41165877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.